Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis

Sponsor
Prince of Songkla University
Study ID
NCT04122547
Phase
PHASE3
Status
Completed

Conditions

  • Bronchiectasis
  • Exacerbation Copd
  • Lung Function Decreased

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Roflumilast — DRUG
    Active drug
  • Placebo — DRUG
    Placebo one tablet oral od

Study Details

Roflumilast compare with placebo for decrease infected exacerbation in non-cystic Bronchiectasis

Key Dates

Start date
Jan 31, 2015
Status verified
Oct 2019
Primary completion
Dec 31, 2015
Completion
Dec 31, 2015

Study Design

Enrollment
40 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Roflumilast
    Roflumilast 500 microgram one tab oral per day
  • Placebo Comparator: Placebo
    One tablet oral per day

Primary Outcome Measure

acute deterioration of of bronchiectasis symptoms [ Time Frame: 6 months ]

Related Studies